The therapeutic effect of dabrafenib combined with trametinib

Two studies of melanoma that have spread to other parts of the body or cannot be removed with surgery used a combination of dabrafenib and trametinib. In one study, 423 patients received dabrafenib either in combination or alone. Patients who took the combination survived 11 months without worsening of their condition, while those who took dabrafenib alone lived 8.8 months. In a second study involving 704 patients, dabrafenib and trametinib were compared with vemurafenib, another melanoma drug. Patients on the combination lived an average of 25.6 months, compared with 18 months in the vemurafenib group.

In a study involving870 patients with surgically removed stage III melanoma, the combination of dabrafenib and trametinib was compared to placebo (dummy treatment) for 1 year. About 40% of patients who received the combination therapy died or had disease recurrence after an average of about 3.5 years, compared with 59% of patients who received a placebo. Dabrafenib is more effective than the cancer drug dacarbazine at controlling melanoma that has spread to other parts of the body or cannot be removed with surgery. This is based on a major study involving 250 patients, which measured how long patients lived before their condition worsened. Patients taking dabrafenib lived an average of 6.9 months before their condition worsened, while those taking dacarbazine lived an average of 2.7 months.

In a major study,171 patients with non-small cell lung cancer were treated with dabrafenib in combination with trametinib or dabrafenib alone. The primary measure of effectiveness is the percentage of patients who respond completely or partially to treatment. Response to treatment is assessed using body scans and the patient's clinical data. The use of dabrafenib in combination with trametinib resulted in responses in more than 60% of patients, compared with 23% of patients using dabrafenib alone.

The original drug of dabrafenib is relatively expensive and has been covered by medical insurance since it was launched in China. Currently only qualified patients can be reimbursed. SpecificationsThe price of each box of 50mg*120 capsules may be around around 10,000. The Turkish version of the original drug Dabrafenib sold overseas, Specifications 75mg*120 capsules, may cost around 10,000 per box (the price may fluctuate due to exchange rates). There are also relatively cheap generics of dabrafenib sold overseas, and their pharmaceutical ingredients are basically the same as those of the original drugs sold domestically and abroad. For example, Specifications produced by Laos Pharmaceutical Factory The price of 75mg*120 tablets per box may be more than 4,000 yuan (the price may fluctuate due to exchange rates).